N
NEOGAP Therapeutics
Imagine if cancer patients who lack efficient treatment options could be cured
About NEOGAP Therapeutics
Developer of personalized cancer immunotherapy designed to precisely target and eliminate cancer. The company's product identifies optimal neoantigens to target, activate and multiply T-lymphocytes with the purpose of eradicating cancer, enabling cancer patients to recover from the disease.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 60.8/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Oncology, Drug Development, EIC, Biotech and Pharma, Hard Tech, Horizon Europe, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Feb 2026 | $11M | $42M | Sciety | ↗ |
| GRANTOther financing | Mar 2024 | $605K | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for NEOGAP Therapeutics is 590 monthly website visits, up 293.3% over the last three months. NEOGAP Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NEOGAP Therapeutics in the Stockholm ecosystem
The NEOGAP Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A1 investor entered at this stage
Sciety
Source: Dealroom Talent Intelligence.
See NEOGAP Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










